BIOLOGY.DIGITAL
Back to Case Studies

Sanofi & Bristol Myers Squibb + Owkin & Tempus AI: Federated Clinical AI & Spatial Multi-Omics

Precision Oncology & BiopharmaGlobal Top-20 Biopharma PartnersTempus AI

📌Key Takeaways

  • 1Sanofi & Bristol Myers Squibb (Precision Oncology & Biopharma, Global Top-20 Biopharma Partners) deployed Tempus AI.
  • 2Multimodal Clinical & Genomic Data Scale: 200+ PB queryable (now 200+ Petabytes across 8M+ de-identified records).
  • 3Biomarker Clinical Trial Site Activation: 90% faster activation (now 10 to 14 business days via TIME Network).
  • 4Implementation timeline: Immediate cloud cohort access via Tempus Lens; 10-14 day rapid site activation via TIME.
**Deployment Snapshot:** - Partner: Sanofi & Bristol Myers Squibb - Platform you're evaluating: Tempus AI - Core domain: Precision Medicine & Diagnostics - Why we track this deployment for our benchmarks: Verified peer-reviewed and public filing milestones

Bridging Genomic Profiling and Longitudinal Clinical Outcomes

Targeted oncology drugs (such as ADCs, KRAS inhibitors, and bispecific T-cell engagers) frequently fail in heterogeneous solid tumor populations when patient selection relies on single-gene immunohistochemistry or DNA panel sequencing alone. AstraZeneca, GSK (in a $300 million multi-year strategic collaboration), and BioNTech partnered with Tempus AI to access de-identified multimodal patient cohorts that pair xT 648-gene DNA sequencing and whole-transcriptome RNA-seq with longitudinal EHR treatment response, progression-free survival, and digitized H&E histopathology. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.

Just-in-Time Biomarker Trial Matching via the TIME Network

Beyond retrospective target and resistance-mechanism discovery in the Tempus Lens environment, sponsors use the Tempus TIME Trial Program to solve precision oncology's hardest operational bottleneck: finding rare molecularly defined patients (such as NRG1 fusions or HER2-low/ultralow breast cancer) at the exact moment of progression. When Tempus sequences a patient's biopsy for routine clinical care and detects a qualifying alteration, the platform alerts the treating community site and activates the clinical trial protocol in as little as 10 to 14 business days. What's the takeaway for your own architecture? We've analyzed this rollout closely, and it's clear you can't separate compute from wet-lab execution. You'll get the best ROI when your scientists and modelers share one data loop.

Multimodal Clinical & Genomic Data Scale

200+ PB queryable

Biomarker Clinical Trial Site Activation

90% faster activation

Top-20 Oncology Pharma Adoption

95% market penetration

The Challenge

DNA-only genomic panels miss transcriptomic ADC target expression and tumor microenvironment immune states, while rare biomarker-driven oncology trials take years to accrue patients. That's a massive bottleneck for any R&D team. If you're running similar programs, you know legacy workflows simply don't scale.

The Solution

Leveraged Tempus Lens multimodal clinicogenomic cohorts (DNA + whole-transcriptome RNA + digital pathology + longitudinal EHR) alongside the Tempus TIME rapid trial activation network. Here's how they fixed it. By pairing Tempus AI with automated wet-lab feedback, we see how you can compress months of manual screening into weeks.

Implementation

Immediate cloud cohort access via Tempus Lens; 10-14 day rapid site activation via TIME

Translational Oncology, Companion Diagnostics (CDx), and Clinical Operations teams

  1. 1Queried de-identified multimodal patient cohorts in Tempus Lens to correlate RNA transcript expression and co-mutations with real-world checkpoint inhibitor and ADC resistance.
  2. 2Validated candidate biomarker signatures on patient-derived tumor organoids (PDOs) in Tempus wet labs.
  3. 3Developed algorithmic pathology and transcriptomic companion diagnostic (CDx) classifiers.
  4. 4Deployed automated molecular eligibility screening across 100+ community oncology sites via the Tempus TIME Trial Network.

Results

MetricBeforeAfterChange
Multimodal Clinical & Genomic Data ScaleIsolated trial cohorts (<1,000 patients)200+ Petabytes across 8M+ de-identified records200+ PB queryable
Biomarker Clinical Trial Site Activation6 to 9 months traditional site startup10 to 14 business days via TIME Network90% faster activation
Top-20 Oncology Pharma AdoptionFragmented registry vendors19 of Top 20 oncology pharma companies95% market penetration
"Combining high-quality multimodal clinical and molecular data with machine learning allows us to better understand patient biology, design smarter trials, and improve probability of clinical success."

Translational Medicine Leadership, Global Oncology Partner

Key Learnings

  • 1Whole-transcriptome RNA-seq paired with DNA sequencing captures fusion transcripts, splice variants, and ADC surface receptor density that DNA-only panels miss.
  • 2Just-in-time trial activation at community oncology clinics dramatically accelerates accrual for biomarker subtypes occurring in <2% of patients.
  • 3Linking digitized H&E pathology slides with molecular calls allows training low-cost histology screening algorithms that pre-identify patients for confirmatory sequencing.

Frequently Asked Questions

Tempus combines broad DNA panel/exome sequencing with routine whole-transcriptome RNA-seq, digitized H&E pathology slides, and longitudinal EHR clinical outcomes in a single de-identified data lake (Tempus Lens), plus patient-derived organoid (PDO) wet-lab validation. If you're negotiating a similar partnership, we recommend benchmarking your internal assay throughput first.
According to Tempus AI SEC S-1 and 10-K filings, 19 of the top 20 global pharmaceutical oncology companies partner with Tempus, highlighted by multi-hundred-million-dollar strategic agreements with GSK ($300M), AstraZeneca, and BioNTech ($200M). If you're negotiating a similar partnership, we recommend benchmarking your internal assay throughput first.
Learn More About Tempus AI

Verified References & Citations (2)

  1. [1]

    GSK and Tempus enter $300M collaboration to advance precision medicine and AI-enabled clinical trial design.

  2. [2]

    BioNTech and Tempus announce strategic collaboration across multimodal oncology datasets.

Last updated: March 1, 2026

Ask AI